Association of serum Tocilizumab trough concentrations with clinical disease activity index scores in adult rheumatoid arthritis patients.
CONCLUSION: In the first 24 weeks of treatment with SC TCZ injections, TCZ concentrations are associated with clinical improvement, while body weight and BMI are inversely associated with TCZ concentrations. Personalizing the dose of SC TCZ to body weight may improve outcomes of clinical disease activity in RA patients. PMID: 31154416 [PubMed - as supplied by publisher]
Authors: Strand V, Shah R, Atzinger C, Zhou J, Clewell J, Ganguli A, Tundia N Abstract Objective: Determine healthcare resource utilization (HCRU) and associated costs associated with fatigue and stiffness among patients with rheumatoid arthritis (RA). Methods: A retrospective claims analysis compared RA patients with fatigue or stiffness to matched RA control patients with neither. Claims from a large U.S. commercial insurance database identified new cases of stiffness/fatigue among newly diagnosed patients. Study patients had ≥2 medical claims for RA ≥45 days apart, continuous insurance coverage ≥12 mont...
Conclusions: Despite individual increases in serum 14-3-3η, HMGB1, anti-CCP, anti-MCV and RF, the combination of anti-CCP and anti-MCV might be of great help for diagnostic in RA, and so should be considered as routine tests for this disease. PMID: 31433746 [PubMed - as supplied by publisher]
Conclusion: Our results show for the first time the relationship between serum levels of galectin and the clinical parameters of patients with RA. Demonstrating their role in pathogenesis, new studies with galectins are needed to assess how they function as a biomarker in RA. PMID: 31428469 [PubMed]
Introduction: Less than 10 cases of cutaneous panniculitides have been reported as adverse reactions to abatacept, with the most common reactions associated with oral contraceptives, nonsteroidal antiinflammatory drugs, antibiotics, and leukotriene-modifying agents. It is vital to recognize panniculitis drug reactions in rheumatologic patients for their future treatment options and the current understanding of cutaneous panniculitides associated with medications.
Cutaneous infections with Mycobacterium haemophilum are rare and usually characterized by tender, erythematous, ulcerating skin nodules. The risk of disease from nontuberculosis mycobacterium increases with progressive immunodeficiency. Here, we report a case of cutaneous mycobacterium infection in a patient on chronic immunosuppression for mixed connective tissue disease (MCTD)/interstitial lung disease (ILD). Our patient was receiving azathioprine, hydroxychloroquine sulfate (Plaquenil), and prednisone for MCTD, ILD, and rheumatoid arthritis.
Pyoderma gangrenosum (PG) is a sterile, idiopathic, ulcerative, neutrophilic dermatosis that can be associated with trauma or systemic diseases. The lesion typically begins as a pustule that later progresses to an ulcer or deep erosion with violaceous undermined borders. Diagnosis of PG is based on histopathology as well as exclusion of other diagnoses. Approximately 50% of PG cases are associated with systemic diseases, which include inflammatory bowel disease (IBD), rheumatoid arthritis, and hematologic malignancies.
The objective of this study is to describe the epidemiological trend of PG patients in a university-based wound care outpatient center, focusing on demographics, comorbidities, and treatments.
A 50-year-old female with history of rheumatoid arthritis presented with a large nodule on right medial knee. The lesion had been present for several years and was progressively growing causing her pain. Recently the lesion had begun to ulcerate and drain a yellow liquid. The patient was on methotrexate 20 mg weekly, hydroxychloroquine 200 mg daily, and prednisone 5 mg daily for her rheumatoid arthritis. On her right medial knee, she had a 6.8 cm soft, slightly compressible, yellowish nodule. The lesion was surgically resected under local anesthesia and the defect primarily repaired.
Background: Multicentric reticulohistiocytosis (MRH) is a rare granulomatous disease characterized by erythematous papulonodules and erosive polyarthritis that often coexist simultaneously. Rheumatoid arthritis (RA) is another disease entity causing both cutaneous and arthritic manifestations. MRH can be misdiagnosed as RA due to similarities in clinical features.